<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815685</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-15190</org_study_id>
    <nct_id>NCT00815685</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia</brief_title>
  <official_title>A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The data collected through this pilot study will allow us to increase our understanding of
      cancer cachexia and the effect of Eicosapentaenoic Acid (EPA) on cancer cachexia. Our
      long-term goal is to improve nutritional treatment and reduce illness in the cancer patient
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People who have cancer can get what is called cancer cachexia (CC). The symptoms of CC
      include getting full quickly when eating (early satiety), loss of appetite, weakness
      resulting in weight loss and loss of lean body mass. Even a weight loss of 5% in cancer
      patients reflects poor health, hospitalization, and a higher rate of illness. Research shows
      that the elderly are at higher risk for deficiency of vitamins and trace minerals. Other
      pre-existing chronic diseases and drug therapies in this population may increase the needs of
      certain nutrients. Recent studies have also shown that advanced malnutrition is much more
      difficult to treat in the elderly than in younger adults, and the consequences of failure to
      treat it delays recovery and can decrease function and quality of life. At this time, the
      ways to treat CC include giving medications to increase appetite and giving nutritional
      supplements that are high in calories and protein.

      Recent studies have shown that certain types of fats that are present in fish, walnuts and
      other foods that we eat called Eicosapentaenoic acid (EPA) may help with weight gain,
      especially gain in muscle and improve quality of life in patients with pancreatic cancer.
      However, EPA has never been studied in prevention of cancer cachexia in cancer patients
      showing early signs of weight loss. Based on these early, small studies, it is clear that we
      need to study if and how EPA can prevent loss of muscle and weight in cancer patients and
      prevent this from becoming worse.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Albumin</measure>
    <time_frame>6 weeks per patient</time_frame>
    <description>Change in protein status at 6 weeks after initial diagnosis of weight loss of &gt;5% body weight as indicated by morphological, biochemical and immunological intermediate biomarkers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Proteasome Activity That Was Inhibited in the Range of 6%-29%.</measure>
    <time_frame>6 weeks per patient</time_frame>
    <description>There is no expected range for &quot;normal&quot; activity since there is not currently a clinical indication for these molecular markers. Comparison of ranges can be made between groups (such as those that received treatment and not). This was an exploration of potential in the pilot study and further research is indicated to better understand the metabolic abnormalities observed in cancer cachexia as well as potential benefits of using agents such as EPA.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Cancer Cachexia</condition>
  <arm_group>
    <arm_group_label>Eicosapentaenoic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eicosapentaenoic Acid</intervention_name>
    <description>Participants will receive Lovaza at a dose of 4 g for 6 weeks. Participants will be examined at six weeks for change in protein status as indicated by change in morphological (Height, weight, body mass index, body composition, lean body mass, body fat %), and biochemical (serum prealbumin) markers of protein status and immunological cytokines (Il-6, TNF- Î±) markers implicated in cancer cachexia. At baseline, 3 and 6 weeks, participants will undergo interviews and laboratory analysis for determining compliance and treatment-related toxicity.</description>
    <arm_group_label>Eicosapentaenoic Acid</arm_group_label>
    <other_name>Lovaza</other_name>
    <other_name>EPA</other_name>
    <other_name>omega-3-acid ethyl esters</other_name>
    <other_name>docosahexaenoic acid</other_name>
    <other_name>DHA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and Women 25-80 years of age (inclusive)

          -  Confirmed diagnosis of Cancer (other than pancreatic cancer) Unintentional weight loss
             of &gt;5% of body weight within 3 months of admission to the study

          -  Use of effective means of contraception (men and women) in patients of child-bearing
             potential

          -  Normal baseline liver function tests (LFTs) as determined by alanine aminotransferase
             (ALT) levels. Common Toxicity Criteria (CTC)) version 3 grade 1 elevation in ALT
             (&gt;Upper Limit of Normal[UNL]-2.5 x UNL) withhold admitting participant to the study
             until recovery to normal; LFTs will be considered valid for consideration of
             eligibility if drawn within the previous 2 weeks, otherwise new labs will be drawn.

          -  Able and willing to give written informed consent : Each participant must be aware of
             the nature of his current medical condition and must be willing to give consent after
             being informed of the experimental nature of therapy, alternatives, potential
             benefits, side-effects, risks and discomforts.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0- 2 (Karnofsky score
             &gt;60%)

          -  Concurrent use of coumadin or warfarin is okay. The follow-up monitoring for
             prothrombin (PT), partial thromboplastin time (PTT) and International Normalized Ratio
             (INR) for patients on warfarin and/or coumadin will follow the standard of care as
             dictated by the prescribing physician. If the prescribing physician is not a Moffitt
             physician, then the prescribing physician will be notified by the research staff of
             the subject participating in the study, and monitors for PT, PTT and INR will be
             obtained from patient during the 6 week study for review.

        Exclusion Criteria:

          -  Patients with current diagnosis or history of pancreatic cancer

          -  Current use of anticoagulants other than coumadin, warfarin, or aspirin

          -  Use of other nutritional supplements other than multivitamins and minerals

          -  Allergy to fish or seafood

          -  Using Marinol or Megace

          -  Known history of hepatic or renal disease

          -  Other acute or chronic medical or psychiatric condition or laboratory abnormality that
             may increase risk associated with study participation or study drug administration, or
             may interfere with interpretation of study results, and in the judgment of the
             investigator would make the patient inappropriate for entry into this study.

          -  Evidence of bleeding diathesis or coagulopathy

          -  Other acute or chronic medical or psychiatric condition or laboratory abnormality that
             may increase risk associated with study participation or study drug administration, or
             may interfere with interpretation of study results, and in the judgment of the
             investigator would make the patient inappropriate for entry into this study

          -  Pregnant (positive pregnancy test) or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagi Kumar, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Martin Memorial</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34997</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2008</study_first_submitted>
  <study_first_submitted_qc>December 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2008</study_first_posted>
  <results_first_submitted>April 27, 2011</results_first_submitted>
  <results_first_submitted_qc>August 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 8, 2011</results_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>n-3 fatty acids</keyword>
  <keyword>nutritional treatment</keyword>
  <keyword>molecular pathogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible participants will include cancer patients with Men and Women &gt;25 years of age (inclusive), with a confirmed diagnosis of cancer, unintentional weight loss of &gt;5% of body weight, using uniform established diagnostic criteria and be admitted to the study within 3 month of diagnosis.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Eicosapentaenoic Acid (Lovaza)</title>
          <description>Participants to receive Lovaza at a dose of 4 g for 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14">Complete pre and post-treatment serum samples were available for 14 participants.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eicosapentaenoic Acid (Lovaza)</title>
          <description>Participants to receive Lovaza at a dose of 4 g for 6 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Albumin</title>
        <description>Change in protein status at 6 weeks after initial diagnosis of weight loss of &gt;5% body weight as indicated by morphological, biochemical and immunological intermediate biomarkers.</description>
        <time_frame>6 weeks per patient</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eicosapentaenoic Acid (Lovaza)</title>
            <description>Participants to receive Lovaza at a dose of 4 g for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Albumin</title>
          <description>Change in protein status at 6 weeks after initial diagnosis of weight loss of &gt;5% body weight as indicated by morphological, biochemical and immunological intermediate biomarkers.</description>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.10" upper_limit="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Proteasome Activity That Was Inhibited in the Range of 6%-29%.</title>
        <description>There is no expected range for ânormalâ activity since there is not currently a clinical indication for these molecular markers. Comparison of ranges can be made between groups (such as those that received treatment and not). This was an exploration of potential in the pilot study and further research is indicated to better understand the metabolic abnormalities observed in cancer cachexia as well as potential benefits of using agents such as EPA.</description>
        <time_frame>6 weeks per patient</time_frame>
        <population>Participants with available pre and post-treatment serum samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Eicosapentaenoic Acid (Lovaza)</title>
            <description>Participants to receive Lovaza at a dose of 4 g for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Proteasome Activity That Was Inhibited in the Range of 6%-29%.</title>
          <description>There is no expected range for ânormalâ activity since there is not currently a clinical indication for these molecular markers. Comparison of ranges can be made between groups (such as those that received treatment and not). This was an exploration of potential in the pilot study and further research is indicated to better understand the metabolic abnormalities observed in cancer cachexia as well as potential benefits of using agents such as EPA.</description>
          <population>Participants with available pre and post-treatment serum samples.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks per participant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eicosapentaenoic Acid (Lovaza)</title>
          <description>Participants to receive Lovaza at a dose of 4 g for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Mucositis/stomach - Oral cavity</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - Chest/Thorax</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - abdomen</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose serum-high</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Potassium serum-low</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CNS</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <description>Grade 2 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hemorrhage: nose</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>International Normalized Ratio of prothrombin time (INR)</sub_title>
                <description>Grade 1-3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <description>Grade 2 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <description>Grade 3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Partial Thromboplastin Time (PTT)</sub_title>
                <description>Grade 1-3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Opthalmoplegia/diplopia (double vision)</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Grade 1-3 - possibly related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Grade 2 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 2 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Distension/bloating, abdominal</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 1 - possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 1-3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - Chest/thorax NOS</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - back</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - head/headache</sub_title>
                <description>Grade 2 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - lymph node</sub_title>
                <description>Grade 1 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - neck</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - sinus</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - stomach</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <description>Grade 2 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>Grade 2 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <description>Grade 1-3 - unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high</sub_title>
                <description>Grade 1-3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low</sub_title>
                <description>Grade 1-3 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <description>Grade 1-3 - unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine color change</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reaction</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Voice changes</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising in absence of Grade 3 or 4 thrombocytopenia</sub_title>
                <description>Grade 1 - unlikely to be related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hair loss</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <description>Grade 1-3 - unlikely to be related</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Grade 1 - unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a Pilot Supportive Care Intervention.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nagi Kumar, Ph.D., via Moffitt Cancer Center</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-6885</phone>
      <email>nagi.kumar@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

